Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Government Agencies›
AirOmatix
AddedFeb 18, 2024
UpdatedJun 18, 2026
AirOmatix

AirOmatix

Operating

AirOmatix: NSF-funded innovator of patented technology for enhanced oxygen concentration and removal.

Founded
2019
Location
Portland, OR, US
Overview
Compare
Employees
Website

Founded with NSF funding, AirOmatix is dedicated to revolutionizing oxygen delivery through its novel, patent-pending technology. The company's core mission is to enhance oxygen concentration and removal from the air, aiming to provide higher oxygen purity and increased flow rates. AirOmatix focuses on developing advanced oxygen concentrators that outperform traditional methods like pressure swing adsorption (PSA) with zeolite, targeting markets in healthcare, industrial applications, and beyond.

Notable affiliated individuals include the founders and key researchers who have secured NSF funding to drive innovation. AirOmatix has achieved significant milestones, including the development of a technology that delivers four times the oxygen flow rate compared to legacy methods. The company's impact is marked by its potential to improve various applications requiring high-purity oxygen, setting new standards in efficiency and performance.

AirOmatix - Quick Facts

When was AirOmatix founded?

AirOmatix was founded in 2019.

Where is AirOmatix's headquarters located?

AirOmatix's headquarters is located in Portland, OR, US.

When was AirOmatix's last funding round?

AirOmatix's most recent funding round was for $50k (USD) in June 2022.

How much has AirOmatix raised to-date?

As of Jun 29, 2022, AirOmatix has raised a total of $306k (USD).

How many employees does AirOmatix have?

AirOmatix has 3 employees as of Feb 4, 2024.

AirOmatix - Classification

Industry
  • Hardware
Ownership
  • Government
Technology
  • Oxygen
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Consumers
  • Enterprise
Main Product
  • Oxygenconcentrators
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified